X4 Pharmaceuticals (XFOR) EPS (Basic) Growth (3y) (2020 - 2025)
X4 Pharmaceuticals (XFOR) EPS (Basic) Growth (3y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - | 53.55% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn | 37.73% |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn | 14.29% |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn | -2.89% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | 86.43% |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 45.89% |
| 10 | X4 Pharmaceuticals | 166.21 Mn | -50.84 Mn | 2.20 Mn | 65.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 65.48% |
| Sep 30, 2025 | 55.64% |
| Jun 30, 2025 | 42.17% |
| Mar 31, 2025 | 26.03% |
| Dec 31, 2024 | 47.82% |
| Sep 30, 2024 | 37.80% |
| Jun 30, 2024 | 37.72% |
| Mar 31, 2024 | 41.55% |
| Dec 31, 2023 | 51.04% |
| Sep 30, 2023 | 76.21% |
| Jun 30, 2023 | 24.13% |
| Mar 31, 2023 | 33.38% |
| Dec 31, 2022 | 21.30% |
| Sep 30, 2022 | 39.99% |
| Jun 30, 2022 | 16.16% |
| Mar 31, 2022 | 52.44% |
| Dec 31, 2021 | 34.87% |
| Sep 30, 2021 | 42.18% |
| Jun 30, 2021 | 36.22% |
| Mar 31, 2021 | 27.49% |